AB0790 ULTRASOUND-GUIDED VERSUS ANATOMICAL LANDMARK INJECTION OF THE SHOULDER JOINT; A RETROSPECTIVE STUDY

Background: Ultrasound is a widely used tool for diagnostic and interventional purposes myriad of musculoskeletal conditions. The question about the value ultrasound-guided injection over blind debatable [1, 2]. Objectives: To test versus subacromial-subdeltoid bursitis, subcoracoid long head biceps synovial sheath, intra-articular shoulder injection. Methods: We included 168 participants (66 52 subcoracoid, 10 with tenosynovitis 38 had adhesive capsulitis performed injection) half them were injected by technique other under ultrasound guidance. All diagnosed ultrasound. methylprednisolone acetate 40 mg (Solumedrol, Pfizer) + lidocaine hydrochloride 1% (Xylocaine Astra Zeneca), 2 ml. SPADI score range motion before immediately after injection, weeks, 4 weeks. Further, complications recorded Results: mean age study group was around 35.5 years, no significant difference between two groups, slightly male predominance (60.7%). similar groups but improvement higher among compared to anatomical landmark-guided group, as showed regarding scores at weeks post-injection. Regarding motion, significantly better one all 4-week course follow up. complication rate non-significant (Table 1). highest cases Conclusion: Ultrasound-guided injections outcomes injections, especially in addition, it less than References: [1]Elsaman A, Hamed Radwan A. epidural block axial spondyloarthritis patients limited spine mobility: randomized controlled trial. Korean Journal Pain 2021; 34: 114. [2]Elsaman AM, Mostafa ES, AR. Ankle Evaluation Active Rheumatoid Arthritis Ultrasound: A Cross-Sectional Study. medicine & biology 2017; 43: 2806-13. Table 1. Comparison – guided (n=84) Anatomic landmark P Age 35.4±9.5 36.0±9.5 0.643 Sex Male 49(58.3%) 53(63.1%) 0.527 Female 35(41.7%) 31(36.9%) Site Subacromial-subdeltoid bursitis 33(39.3%) 0.998 Subcoracoid 26(31%) 27(32.1%) Long 5(6%) Adhesive 20(23.8%) 19(22.6%) Pre-injection 55.8±9.4 54.7±10.1 0.466 Immediately post-injection 48.6±8.2 51.2±8.9 0.051 44.9±10.1 49.6±9.3 0.002 42.4±9.7 47.6±7.8 0.001 Range (percent) 33.6±9.7% 29.4±11.2% 0.010 37.2±8.5% 32.7±9.9% 40.1±7.3% 33.6±8.3% <0.001 Complications 12(14.3%) 0.164 Bleeding 3(3.6%) 8(9.5%) 0.119 Vasovagal attack 4(4.8%) 0.699 Disclosure Interests: None declared